Get App
Last Updated : Jun 11, 2019 11:25 AM IST | Source:

Sun Pharma drops 4% after Goldman Sachs downgrades to sell

The global financial firm attributed the downgrade to Sun Pharma's spending in speciality pharma which will impact the company's profit growth.

Moneycontrol News @moneycontrolcom

Shares of Sun Pharma dropped nearly 4 percent intraday on June 11 after brokerage firm Goldman Sachs downgraded the stock to sell and cut the target price from Rs 437 to Rs 355.

The global financial firm attributed the downgrade to Sun Pharma's spending in speciality pharma which will impact the company's profit growth.

The company had reported a 52.63 percent decline in consolidated profit at Rs 635.88 crore for the quarter ended March 31, 2019.


The company had a net profit of Rs 1,342 crore in the same quarter last year.

At 1122 hrs, Sun Pharma was quoting Rs 386.95, down 3.71 percent on the BSE.

Subscribe to Moneycontrol Pro and gain access to curated markets data, exclusive trading recommendations, independent equity analysis, actionable investment ideas, nuanced takes on macro, corporate and policy actions, practical insights from market gurus and much more.
First Published on Jun 11, 2019 11:25 am
Follow us on
Available On
PCI DSS Compliant